Rollout of Janssen Vaccine in Europe Postponed Due to Possible Blood Clots

0 13,896

Pharmaceutical Johnson & Johnson is delaying the Janssen corona vaccine rollout in Europe as a precaution because of possible blood clots that can develop in people receiving the vaccine.

 

This is reported by the pharmaceutical company, which has decided to postpone it on medical authorities’ advice in the United States.

This is because six cases have surfaced in the US of a severe complication, cerebral sinus vein thrombosis (CVST), combined with a low platelet count (thrombocytopenia).

This complication was diagnosed in six women between 18 and 48 within two weeks of administering the Janssen shot. One woman died, another is in critical condition in hospital, the New York Times reports.

The Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) already stopped using the Janssen vaccine at federal injection sites today. Individual states were also advised to stop pending further investigation.

That should reveal whether there is a relationship between the vaccine and the complications that have occurred. Scientists from both health authorities were due to meet tomorrow for an emergency meeting.

Leave A Reply